Evidence map›Paper›PMID 34688420›Full record

ReviewThe Medical clinics of North America2021

Evolving Concepts of Type 2 Diabetes Management.

Layla A Abushamat, Jane E B Reusch

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Medical clinics of North America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Layla A AbushamatDivision of Endocrinology, Metabolism, and Diabetes, University of Colorado School of Medicine, MS 8106, 12801 East 17th Avenue, Room 7103, Aurora, CO 80045, USA. Electronic address: layla.abushamat@cuanschutz.edu.
Jane E B ReuschDivision of Endocrinology, Metabolism, and Diabetes, University of Colorado School of Medicine, MS 8106, 12801 East 17th Avenue, Room 7103, Aurora, CO 80045, USA; Ludeman Family Center for Women's Health Research, 12348 East Montview Boulevard, Mail Stop C-263, Aurora, CO 80045 USA; Rocky Mountain Regional Veteran Affairs Medical Center, 1700 North Wheeling Street, Aurora, CO 80045, USA.
University of Colorado Denver · US

Funding

University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI PETER J DEMPSEY · 2020 to 2026
$10.8M
Role of Microvascular insulin resistance and cardiorespiratory fitness in diabetesR01DK124344 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI ZHENQI LIU, JUDITH G. REGENSTEINER · 2021 to 2026
$3.5M
CSRD VA I01 CX001532NIDDK NIH HHS P30 DK116073NIDDK NIH HHS R01 DK124344
6 · The paper itself

Abstract

With the concept of patient-centered care in mind, this article outlines the current diabetes medications available for glucose lowering and the characteristics of each of these medications that need to be considered in shared decision-making for durable and effective therapy. Important patient characteristics such as weight, risk for hypoglycemia, cost, social determinants of health, and medical literacy need to be considered. The evidence-base informing the use of antihyperglycemic agents has changed dramatically due to 2008 FDA guidance for cardiovascular safety and cardiorenal protection with antihyperglycemic agents. New evidence supports an approach to diabetes management that addresses pre-existing cardiorenal disease.

Indexed as

Cardiovascular DiseasesClinical Trials as TopicComorbidityDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug Therapy, CombinationGlucagon-Like Peptide-1 Receptor AgonistsHumansHypoglycemic AgentsInsulinLife StylePractice Guidelines as TopicProspective StudiesRenal Insufficiency, ChronicRisk FactorsSodium-Glucose Transporter 2 Inhibitors2,4-thiazolidinedioneDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInsulinSodium-Glucose Transporter 2 InhibitorsSulfonylurea CompoundsThiazolidinedionesAtherosclerotic cardiovascular diseaseCostHeart failureMicrovascular complicationsObesityPatient-centered careType 2 diabetes

Identifiers

PMID34688420
PMCPMC13012870
OpenAlexW3200330589

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.